Diagnosing, selecting therapy for, and monitoring cancer in patients using a minimally
invasive blood test represents a significant advance in precision medicine. Wide variability …

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real‐
time follow‐up of cancer and overcomes many limitations of tissue biopsies. Epigenetic …

Background Lung cancer screening with low-dose chest CT (LDCT) reduces the mortality of
eligible individuals. Blood signatures might act as a standalone screening tool, refine the …

The detection of cancer at an early stage while it is curable by surgical resection is widely
believed to be one of the most effective strategies for reducing cancer mortality. Hence, the …

Lung cancer is the leading worldwide cause of cancer mortality, as it is often detected at an
advanced stage. Since 2011, low-dose CT scan–based screening has promised a 20 …

Identifying novel circulating biomarkers predictive of response and informative about the
mechanisms of resistance, is the new challenge for breast cancer (BC) management. The …

Cancer remains one of the main causes of human mortality despite significant progress in its
diagnostics and therapy achieved in the past decade. Massive hypomethylation of …

There are numerous reports of cancers in Gaucher disease (GD) from mostly small single‐
center studies; however, precise risk estimates and cancer types involved have not been …

Cell-free DNA (cfDNA) present in the bloodstream or other bodily fluids holds potential as a
noninvasive diagnostic for early disease detection. However, it remains unclear what cfDNA …

Simple Summary Bladder cancer (BC) is the tenth most common cancer worldwide, with
approximatively 550,000 new cases and 200,000 deaths in 2018. BC is divided into two …